Lumera Scientist Previews Company's Therapeutic Antibody Drug Discovery Products
Complete the form below to unlock access to ALL audio articles.
Lumera Corporation, Surface Scientist Christina Boozer, Ph.D., has presented a research poster describing the company's proprietary technology and product development activities relating to therapeutic antibody drug discovery at the Annual Meeting of the Society for Biomolecular Sciences.
The presentation detailed the analysis of a high density antibody microarray for potential drug discovery "hits" to the cancer antigen Carcino Embryonic Antigen (CEA).
Using the ProteomicProcessor™ and NanoCapture™ microarrays , Lumera scientists demonstrated a method by which various antibodies specific to CEA can be detected.
"Dr. Boozer's presentation was well received by researchers in attendance, specifically those looking for new tools and applications which provide specificity profiling in a high throughput, label free format," said the Director of Lumera's Bioscience Unit Dr. Tim Londergan.
"With the presentation of this research poster, we are paving the way for the commercial launch of the ProteomicProcessor™ in early next year, which will be targeted at the therapeutic antibody market."
